Literature DB >> 434972

Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients.

S Ribot, M Rothstein, M Goldblat, M Grasso.   

Abstract

Follow-up studies were done on 231 hemodialysis patients during a period of from one to 48 months to determine the natural history of hepatitis B surface antigenemia (HBs Ag). Of those studied, 113 (49%) exhibited HBs Ag. The probability of remaining HBs Ag positive over the mean follow-up period of 14.4 months was 62%. All of the 38 patients whose HBs Ag reverted to negative did so within ten months. Those patients whose HBs Ag reverted to negative had SGOT levels that were less frequently elevated than the patients with persistent antigenemia. Of hemodialysis patients with HBs Ag, 60% showed e antigen (HBe Ag).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434972

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon.

Authors:  Antoine Abou Rached; Lara El Khoury; Talal El Imad; Abdallah S Geara; Josette Jreijiry; Walid Ammar
Journal:  World J Nephrol       Date:  2016-01-06

3.  Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.

Authors:  Hyung Woo Kim; Young Su Joo; Shin Chan Kang; Hee Byung Koh; Seung Hyeok Han; Tae-Hyun Yoo; Shin-Wook Kang; Jung Tak Park
Journal:  Sci Rep       Date:  2022-06-25       Impact factor: 4.996

4.  Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster.

Authors:  Giorgio Calisti; Omar Herman; Michelle Powley; Tanzina Haque
Journal:  BMJ Case Rep       Date:  2014-06-10

5.  Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination.

Authors:  Ya-Wen Yang; Meng-Kun Tsai; Ching-Yao Yang; Chih-Yuan Lee; Bor-Luen Chiang; Hong-Shiee Lai
Journal:  Clin Exp Nephrol       Date:  2020-03-26       Impact factor: 2.801

Review 6.  [Secondary immune deficiency in renal failure exemplified by hepatitis B vaccination].

Authors:  H Köhler; H Dumann; K H Meyer zum Büschenfelde; S Meuer
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 7.  Viral hepatitis in hemodialysis: An update.

Authors:  Bassam Bernieh
Journal:  J Transl Int Med       Date:  2015-09-30

8.  Evaluation of Response to Hepatitis B Vaccination in Chronic Hemodialysis Patients.

Authors:  Samir H Almueilo
Journal:  Saudi J Med Med Sci       Date:  2017-08-21

9.  Prevalence of overt and occult hepatitis B virus infections among 135 haemodialysis patients attending a haemodialysis centre at Al-Nasiriyah city, Iraq.

Authors:  Muslim Dhahr Musa; Hekmat Kadhum Ateya
Journal:  Iran J Microbiol       Date:  2020-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.